Treatment of an orchiectomized patient with hormone-refractory prostate cancer with LH-RH agonists.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11713406.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This report confirms experimental data on direct inhibitory effects of LH-RH agonists in growth control of human prostate cancer cells. The patient had hormone-refractory prostatic carcinoma after hormonal therapy, including orchiectomy, and responded successfully to a 6-month treatment with goserelin acetate (3.6 mg depot s.c.). The treatment has led to a reduction of tumor mass and metastases as well as an improvement in the patient's paraclinical indicators and general status. The remission lasted 14 months. The treatment still continues.
Medical subject headings
- Adenocarcinoma
- Antineoplastic Agents, Hormonal
- Gonadotropin-Releasing Hormone
- Goserelin
- Prostatic Neoplasms